Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 12/20 | 0.74 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.59 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9752255 | 1.00 | NOD1 (0.74) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL15544362 | 1.00 | NOD1 (0.74) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL9752230 | 1.00 | NOD1 (0.74) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL9752247 | 1.00 | NOD1 (0.74) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL9752251 | 1.00 | NOD1 (0.74) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL16190327 | 1.00 | NOD1 (0.74) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL16190302 | 1.00 | NOD1 (0.74) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL9752254 | 1.00 | NOD1 (0.74) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL16190303 | 1.00 | NOD1 (0.74) | NOD1SLC6A5FAAHMEN1MAPK1 | |
| SCHEMBL9752248 | 1.00 | NOD1 (0.74) | NOD1SLC6A5FAAHMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | claimed |
| EP-4684872-A1 | DEVICE AND METHOD FOR WATER-IN-AIR GENERATION OF DROPLETS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-01-28 | — | — | EP | claimed |
| US-12251469-B2 | Sterically stabilized carrier compositions for treating a mammal | VGSK TECHNOLOGIES, INC. (US) | 2025-03-18 | — | — | US | claimed |
| CN-118986923-A | Targeted polysaccharide nanoparticle composition for reversing tumor multi-drug resistance, preparation method and application thereof | 暨南大学 | 2024-11-22 | — | — | CN | claimed |
| CN-118986925-A | Polysaccharide nanoparticle composition for reversing tumor multi-drug resistance, preparation method and application thereof | 暨南大学 | 2024-11-22 | — | — | CN | claimed |
| CN-118986924-A | Long-circulating polysaccharide nanoparticle composition for reversing tumor multi-drug resistance, and preparation method and application thereof | 暨南大学 | 2024-11-22 | — | — | CN | claimed |
| EP-4380579-A1 | MIRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF | Leadermed Champion Limited (CN) | 2024-06-12 | — | — | EP | claimed |
| US-20240180835-A1 | STERICALLY STABILIZED CARRIER COMPOSITIONS FOR TREATING A MAMMAL | VGSK TECHNOLOGIES, INC. | 2024-06-06 | — | — | US | claimed |
| CN-117813099-A | miRNA-based compositions and methods of use thereof | 领康冠军有限公司 | 2024-04-02 | — | — | CN | claimed |
| EP-4333809-A1 | LIPOSOME-ENCAPSULATED CORTICOSTERIODS INHIBIT SARS-COV-2 REPLICATION AND REDUCES LUNG INFLAMMATION | VGSK Technologies, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| WO-1995032006-A1 | GAS FILLED MICROSPHERES AS COMPUTED TOMOGRAPHY CONTRAST AGENTS | IMARX, PHARMACEUTICAL CORP. (US) | 1995-11-30 | — | — | WO | claimed |
| WO-1995024184-A1 | GAS FILLED MICROSPHERES AS MAGNETIC RESONANCE IMAGING CONTRAST AGENTS | UNGER EVAN C (US) | 1995-09-14 | — | — | WO | claimed |
| WO-1995015118-A1 | GAS MICROSPHERES FOR TOPICAL AND SUBCUTANEOUS APPLICATION | IMARX PHARMACEUTICAL CORP. (US) | 1995-06-08 | — | — | WO | claimed |
| WO-1994028780-A2 | METHODS OF PREPARING GAS AND GASEOUS PRECURSOR-FILLED MICROSPHERES | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | claimed |
| WO-1994028874-A1 | NOVEL THERAPEUTIC DELIVERY SYSTEMS | UNGER EVAN C (US) | 1994-12-22 | — | — | WO | claimed |
| US-5283122-A | Solution containing fatty acid and cephalin | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1994-02-01 | — | — | US | claimed |
| US-4789633-A | SUSPENSION WITH PALMITOYL HOMOCYSTEINE; ACIDIFICATION | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1988-12-06 | — | — | US | claimed |
| EP-0179126-A4 | FUSED LIPOSOME AND ACID INDUCED METHOD FOR LIPOSOME FUSION. | UNIV TENNESSEE RES CORP (US) | 1987-08-12 | — | — | EP | claimed |
| EP-0179126-A1 | FUSED LIPOSOME AND ACID INDUCED METHOD FOR LIPOSOME FUSION | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1986-04-30 | — | — | EP | claimed |
| WO-1985004880-A1 | FUSED LIPOSOME AND ACID INDUCED METHOD FOR LIPOSOME FUSION | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1985-11-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | NOD1 2020/4885SLC6A5 4059/4885FAAH 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.